Kodiak Sciences (KOD) closed at $99.30 on November 6, 2026, up 9.1% from the previous close, on volume of 892,958 shares (30-day average 2,833,254).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Call Spread | 16-Oct-26 : 15-Jan-27 55 C | 6,408 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
PRNewswire (Wed, 7-Oct 7:00 AM ET)
4 Explosive Stories Enter the Investor Spotlight
Globe Newswire (Mon, 28-Sep 11:51 AM ET)
Market Chameleon (Mon, 28-Sep 5:52 AM ET)
Kodiak Sciences Sets Sept. 28 Webcast for DAYBREAK Phase 3 Topline Results in Wet AMD
Market Chameleon (Mon, 28-Sep 3:06 AM ET)
PRNewswire (Fri, 25-Sep 6:02 PM ET)
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PRNewswire (Thu, 13-Aug 4:00 PM ET)
PRNewswire (Mon, 10-Aug 4:44 PM ET)
Market Chameleon (Wed, 1-Apr 5:47 AM ET)
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences trades on the NASDAQ stock market under the symbol KOD.
As of November 9, 2026, KOD stock price climbed to $104.40 with 662,109 million shares trading.
KOD has a beta of 1.12, meaning it tends to be more sensitive to market movements. KOD has a correlation of 0.01 to the broad based SPY ETF.
KOD has a market cap of $6.56 billion. This is considered a Mid Cap stock.
In the last 3 years, KOD traded as high as $107.53 and as low as $1.59.
The top ETF exchange traded funds that KOD belongs to (by Net Assets): XBI, VTI, IWM, IBB, VXF.
KOD has outperformed the market in the last year with a price return of +517.8% while the SPY ETF gained +13.4%. KOD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +130.0% and +19.1%, respectively, while the SPY returned -1.9% and -1.0%, respectively.
KOD support price is $94.09 and resistance is $104.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KOD shares will trade within this expected range on the day.
